The perils of selective journalism

/ By / Innovation

Image from here Around two weeks ago, I received an email from Srinivas Rao, editor of Bio-Spectrum, asking me for permission to use some of the information that I had unearthed from CSIR using the RTI Act, 2005. The two specific posts that he wanted to refer to are: “CSIR finally discloses details of patent licensing: More than 400 patents licensed over last ten years” and “CSIR provides misleading information; aims to hide revenues from patent licensing”.  I obviously thought […]

The perils of selective journalism Read More »

Defensive Patent Licensing: A way out of the Patent Quagmire?

/ By / Patent

[Warning: Long post that mostly reviews a paper describing a type of license which may reduce unnecessary patent litigation as well as promote an ‘open access’ approach. Actual review starts from below the dotted line. ] Who would’ve thought patent-wars could have become a topic of discussion amongst even those with traditionally no interest in ‘lawyery stuff’! Good or bad, one side effect that the Apple-Samsung fiasco has had, has been to turn the public’s attention span towards the topic

Defensive Patent Licensing: A way out of the Patent Quagmire? Read More »

Delhi High Court seeks to break the Myth of ‘Breaking Sports News’: New Delhi Television Ltd. v. ICC Development (Intl.) Ltd.

/ By / Copyright

[Image taken from here] In a very recent decision that promises to change the aspect of legally permissible ‘breaking news’, especially regarding sports events, the Delhi High Court has sought to lay down certain cogent principles which the Spicy IP team brings as follows for the benefit of the readers. [Warning: Long Post]   Case name: New Delhi Television Ltd. (Appellant) v. ICC Development (International) Ltd. & Another (Respondent) [(FAO) OS 460/2012]   Date of Judgment : October 11, 2012

Delhi High Court seeks to break the Myth of ‘Breaking Sports News’: New Delhi Television Ltd. v. ICC Development (Intl.) Ltd. Read More »

DU Photocopy Case: Who’s Afraid of Copyright?

/ By / Copyright

–> The Delhi University photocopy case, an unsavoury law suit that pits the interests of private publishing houses against the interests of students and educational establishments, was debated by us extensively in posts here, here, here and here.  At least as pleaded in the law suit, the alleged instances of copyright infringement pertain only to educational “course packs” and the vast majority of takings amount to no more than 10% of copyrighted material. We now bring you a guest post

DU Photocopy Case: Who’s Afraid of Copyright? Read More »

Guest Post: Exide v. Exide: Too much Exidement?

/ By / Trademark

Our regular guest blogger, Arun Mohan, a practising IP lawyer before the Madras High Court has sent us this very interesting post analysing in detail the recent Exide judgement of the Delhi High Court and its implications for Indian businesses. The case took fifteen years to come to a resolution and even that happened only after one set of lawyers were changed by one of the parties. It helped that the presiding judge was Justice Valmiki Mehta, an exceptional judge

Guest Post: Exide v. Exide: Too much Exidement? Read More »

Guest Post: The New India Guidelines on Similar Biologics

/ By / Drug Regulation

The Government of India has recently announced certain guidelines regulating the approval of ‘similar biologics’ also known as bio-similars. The bio-similar market is going to be a huge market opportunity for the generic drug industry. Given the complexity of the products themselves, the regulatory regime for bio-similars is also rather complex. Since none of us on the blog had a detailed understanding of the guidelines, we invited our frequent guest blogger Mr. Christopher Ohly to write us a guest post

Guest Post: The New India Guidelines on Similar Biologics Read More »

Intellectual Property Rights: Infringement and Remedies – a book by Ananth Padmanabhan

/ By / Uncategorized

I’m proud to inform our readers that Ananth Padmanabhan, my friend and lawyer, has FINALLY, after four years, published his book Intellectual Property Rights: Infringement and Remedies (LexisNexis Butterworths Wadhwa 2012). Actually, in hindsight, four years is not a very long time to write a book, especially since I’m tried and failed to write a book in a much longer time span. Interested readers can buy the book from here at and there is a standard 10% discount for those

Intellectual Property Rights: Infringement and Remedies – a book by Ananth Padmanabhan Read More »

More controversy during appointments to IPAB: Delhi HC rules against DIPP

/ By / Uncategorized

Image from here. In a decision dated 3rd October, 2012 the Delhi High Court in a judgment by Justice Suresh Kait has ordered the Department of Industrial Policy & Promotion (DIPP) to forward to the Appointment Committee of Cabinets (ACC) the final recommendations of the Selection Committee which had interviewed applicants for the position of Technical Member at the Intellectual Property Appellate Board (IPAB). The judgment can be accessed over here.  The Selection Committee, constituted by the DIPP, had initially

More controversy during appointments to IPAB: Delhi HC rules against DIPP Read More »

SpicyIP Weekly Review (October Week 1)

/ By / Uncategorized

Top of the news this week is the decision of the Division Bench of the Delhi High Court which recognized the doctrine of ‘international exhaustion’ under domestic trademark law. The decision partially allowed the appeal against the order of the Single Judge in Samsung Electronics Co. Ltd. v. Kapil Wadhwa & Ors dated February 17, 2012. The Bench stated that an erroneous approach by the Single Judge led to an incorrect interpretation of the Trade Marks Act, wherein it was

SpicyIP Weekly Review (October Week 1) Read More »

SC on the new drug policy

/ By / Uncategorized

The Supreme Court on last Wednesday gave the government a week to come up with a timeline for implementing its new drug-pricing policy. In the event of failure to comply with the Order, the Court will issue an interim order placing all the 348 medicines within the ambit of price-cap regime based on a product’s manufacturing cost. [See herefor Livemint report.] I blogged on the issue earlier. [See here.] The Group of Ministers (GoM), headed by Agriculture Minister Mr. Sharad

SC on the new drug policy Read More »

Scroll to Top